When observed in elderly hypertensive patients, increased pulse pressure (PP) and arterial stiffness are known to be independent risk factors for cardiovascular diseases. Increased systolic blood pressure (SBP) leads to left ventricular hypertrophy, while decreased diastolic blood pressure (DBP) results in decreased coronary circulation. It is known that increased arterial stiffness is the major cause of increased PP.
Introduction
The percentage of hypertensive patients who are also elderly is increasing. Hypertension in the elderly is characterized by systolic hypertension, with increased systolic blood pressure (SBP) as a risk factor rather than increased diastolic blood pressure (DBP), and increased pulse pressure (PP) is regarded as critical (1) (2) (3) (4) (5) (6) (7) . Pulse pressure is regulated by stroke volume as well as the extensibility of elastic arteries, which are vulnerable to arterial stiffness. Increased arterial stiffness and PP are known to be independent risk factors for cardiovascu-enzyme inhibitor (ACE-I), and long-acting Ca antagonists on arterial stiffness measured by pulse wave velocity and PP.
Methods

Subjects
We compared the brachial-ankle pulse wave velocity (baPWV)-reducing effects in 76 male hypertensive patients aged 65 years or older who visited the outpatient clinic of our hospital. All patients were devoid of complications such as diabetes mellitus, hyperlipidemia, hyperuricemia, and obstructive arteriosclerosis, and either had no history of antihypertensive treatment or had received no antihypertensive drugs for over 4 weeks. Patients diagnosed with moderate or more severe hypertension based on casual BP measurement were included, while patients with secondary hypertension were excluded. Diagnosis of hypertension was done to calculate the mean value of BP for three times. Subjects were randomly assigned to one of four groups for treatment with the following drugs: ARB (valsartan), ACE-I (temocapril), Land N-type Ca-channel blocker (cilnidipine), or L-type Cachannel blocker (nifedipine CR). As a rule, the subjects were treated with a single agent for 3 months. After the initial dose, serum biochemistry tests and urinalysis were regularly performed, and BP was regularly measured. As efficacy endpoints, baPWV and casual BP (sitting position) were measured and recorded at baseline and 3 months after initiation of treatment. An oral daily dose of 80 mg/day of valsartan (Novartis Pharma K.K., Tokyo, Japan), 2-4 mg/day of temocapril (Sankyo Co., Ltd., Tokyo, Japan), 10 mg/day of cilnidipine (Mochida Pharmaceutical Co., Ltd., Tokyo, Japan), or 20 mg/day of nifedipine CR (Bayer Yakuhin, Ltd., Osaka, Japan) was administered once a day in the morning. baPWV was determined from pulse waves measured on the right forearm and right ankle using form pulse wave velosity (PWV) (Colin Corp., Aichi, Japan). Two inspectors performed multiple measurements to validate the inter-observer and intra-observer reproducibility of baPWV.
Prior to the study, all patients provided their informed written consent after receiving an explanation of the contents of this study, the potential adverse reactions associated with each agent, and the policies of patient privacy of our institution. The study protocol was approved by the Institutional Ethical Committee.
Statistical Analysis
Data are expressed as the mean SD. Significant differences among the four groups were determined using one-way analysis of variance (ANOVA) combined with Scheffe's post hoc test, and the χ 2 test where appropriate. Single linear regression analysis was used to evaluate the relation between change in baPWA and changes in BP (systolic, diastolic, mean and pulse). Repeated-measures of ANOVA were used to test for differences in BP and heart rate in each group. Differences of p 0.05 were considered to indicate statistical significance.
Results
Subject Demographics
Subject baseline demographics are shown in Hypertens Res Vol. 26, No. 8 (2003) SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; n.s., not significant. 
Brachial-Ankle Pulse Wave Velocity (baPWV)
BaPWV was significantly decreased in the valsartan, temocapril, and cilnidipine groups ( p 0.01), but remained unchanged in the nifedipine CR group. The reductions in baPWV (∆baPWV: baPWV at 3 months after initiation of treatment baseline baPWV) are shown in Fig. 1 . The value of ∆baPWV in the nifedipine CR group (9 146 cm/s) was significantly lower than that in the valsartan (409 90 cm/s), temocapril (281 99 cm/s), or cilnidipine (209 82 cm/s) groups ( p 0.01, respectively). ∆baPWV was significantly greater in the valsartan group than in the temocapril or cilnidipine groups ( p 0.01).
Correlation between baPWV and Changes in Blood Pressure ( PP, SBP, DBP, MBP)
∆baPWV and ∆PP were significantly correlated in all 76 patients (r 0.62, p 0.001), suggesting that reduction in PP contributes to improvement of arterial stiffness. As shown in Table 3 , however, the examination of individual groups revealed varying results, i.e., ∆baPWV and ∆PP were not PWV, pulse wave velosity; ∆, difference between 3 months after treatment; SBP, systolic blood pressure; DBP, diastolic blood pressure;
MBP, mean blood pressure; PP, pulse pressure. p 0.05, p 0.01. , and significantly correlated in the nifedipine CR group (r 0.82, p 0.01). In the groups given temocapril, cilnidipine, or nifedipine CR, ∆baPWV exhibited a significant correlation with at least one of the parameters of BP change (∆PP, ∆SBP, ∆DBP, ∆MBP), whereas in the valsartan group no such correlation was noted between ∆baPWV and any of ∆PP, ∆SBP, ∆DBP, and ∆MBP.
Discussion
Arteriosclerosis is associated with morphological alterations such as hypertrophy and stenosis as well as functional alterations such as loss of arterial wall elasticity or sclerosis, which are regarded as arterial stiffness and thus are distinguished from arteriosclerosis. In recent years, however, arterial PWV has been shown to be a good marker of arterial stiffness (8, 9, 11) and to be an excellent predictor of the prognosis of hypertension (12, 13) . It has been reported that the risk of cardiovascular disease increases as PWV increases, and that PWV can therefore be an excellent predictor of fatal cardiovascular disease (13) . Arteriosclerosis due to aging, and increased arterial stiffness in particular, decreases the Windkessel function responsible for buffering BP increase, thereby increasing SBP and decreasing DBP. Moreover, an increase in PWV associated with arteriosclerosis leads to elevation of SBP mediated by reflex waves. As a result, PP may also be elevated in elderly hypertensive patients. The authors of a follow-up investigation of the Framingham heart study (1) reported that, among subjects with similar DBP, those with higher SBP showed a higher risk of coronary diseases, while among subjects with similar SBP, those with lower DBP showed a higher risk of coronary diseases. Based on these findings, they concluded that increased PP may be an even greater risk factor for coronary disease than increased SBP and DBP. The Survival and Ventricular Enlargement trial (SAVE) and Studies of Left Ventricular Dysfunction (SOLVD) series also reported that increased PP was an independent risk factor for allcause deaths and cardiovascular mortality (4, 5) . A metaanalysis of the data from large-scale clinical studies in elderly hypertensive patients found that increased PP was a critical risk factor for deaths and cardiovascular events (3). Based on the above, we hypothesized that an improvement of the arterial stiffness and a decrease in PP could reduce the risk of cardiovascular events in hypertensive patients. We therefore investigated the effects of various antihypertensive agents on PWV and PP in elderly hypertensive patients.
We recorded PP waveforms in the right forearm and right ankle simultaneously using a simple, non-invasive oscillometric method and determined baPWV as an index of arterial stiffness to examine the effects of various antihypertensive agents in hypertensive patients. Studies have reported that baPWV exhibits a strong correlation with carotid-femoral PWV determined by the tonometric method (14, 15) . Because a large-scale investigation trial using PWV as an endpoint reported that perindopril (ACE-I) significantly reduced PWV (16), we selected an ACE-I, temocapril (17, 18) , as a control drug. Other antihypertensive agents selected for the study were an ARB (valsartan) (19, 20) and two Cachannel blockers. One of the Ca-channel blockers was an Ltype Ca-channel blocker (nifedipine CR), which blocks only L-type Ca-channels present in vascular smooth muscle, and the other was an L-and N-type Ca-channel blocker (cilnidipine), which blocks L-type Ca-channels as well as N-type Ca-channels present in sympathetic nerve endings and also has a sympatholytic effect (21) (22) (23) .
Valsartan, temocapril, cilnidipine, and nifedipine CR each significantly decreased SBP and DBP. However, ∆DBP was significantly greater in the nifedipine CR group than in the other three treatment groups ( p 0.01). As a result, PP remained unchanged after treatment in the nifedipine CR group, but was significantly decreased in the other three treatment groups. Although a significant difference was found in ∆SBP between the temocapril group and nifedipine CR group, small ∆DBP resulted in a decrease in PP in the temocapril group.
Similar to PP, baPWV was significantly decreased in the valsartan, temocapril, and cilnidipine groups, but exhibited little change in the nifedipine CR group. Furthermore, while baPWV was improved in each of the valsartan, temocapril, and cilnidipine groups, the baPWV increase in the valsartan group was significantly higher than that in the other two groups. Wilkinson et al. (24) reported that intravenous administration of angiotensin II and norepinephrine increased Fig. 1 . Changes in the brachial-ankle pulse wave velocity (∆baPWV) between baseline and 3 months after the administration of each agent. Statistically significant reductions of baPWV compared with the baseline values were seen in the valsartan, temocapril, and cilnidipine groups. ∆baPWV was lowest in the nifedipine CR group. ∆baPWV was significantly higher in the valsartan group than in the other groups.
arterial wall stiffness and that norepinephrine increased PP. Another study reported that AT1 receptor genotypes were involved in an age-related increase in aortic stiffness in hypertensive patients (25) . A further study reported that although alteration in arterial structure may be important in improving arterial stiffness, ARBs inhibited collagen accumulation in the aorta in an experimental model (26) . These findings may explain the present findings that ARB, ACE-I, and an L-and N-type Ca-channel blocker, all of which inhibit the release of norepinephrine, improved both PWV and PP.
It has been found that nitric oxide (NO) donors such as sinitrodil decrease arterial stiffness and PP without much effect on vascular resistance and DBP (27, 28) , and another study reported that doxazosin, an α-blocker, promotes NO production, thereby contributing to improvement of arterial stiffness (29) . Thus, the enhancement of NO production by valsartan (30) , temocapril (31) , cilnidipine (32) , and nifedipine (33) , may have contributed to the results observed in this study. However, the beneficial effect of valsartan on ∆baPWV might have been due not only to NO production, but also to enhancement of AT2 receptors through AT1 receptor blockade (30) .
The present study found the largest baPWV-reducing effect in the ARB group. Concerning the mechanism of reduction of baPWV, since a significant correlation was found between ∆baPWV and at least one of ∆PP, ∆SBP, ∆DBP, and ∆MBP with ACE-I and two Ca-channel blockers, changes in BP may nonetheless be associated with improvement of arteriosclerosis. However, ∆baPWV did not correlate with any one of ∆PP, ∆SBP, ∆DBP, and ∆MBP with ARB, suggesting the importance of blockade of angiotensin receptors in addition to antihypertensive effect in improving arterial stiffness.
In conclusion, since it has been demonstrated that arterial stiffness and increased PP are risk factors for the onset of cardiovascular diseases, it is necessary to take these factors into consideration in the treatment of hypertension. In the present study, the effects of antihypertensive agents on PP and arterial stiffness in elderly hypertensive patients varied among drug classes. These results suggested that PWV is regulated not only by BP but also by changes in the nature of the arterial wall resulting from continuous hypertension (34) , and that ACE-I reduces aortic collagen (26) by a mechanism of action not involving bradykinin but blockade of angiotensin receptors instead. The results of the present study suggest that although ARBs, ACE-Is, and L-and N-type Cachannel blockers reduce the risk of arteriosclerosis by decreasing arterial stiffness in addition to exerting an antihypertensive effect, ARB may further reduce the risk of arteriosclerosis in elderly hypertensive patients.
